Last March 31 I published the story of one of the first 45 volunteers who started the trial of the Moderna vaccine we are talking about today.
In an effectiveness “race”, immediately after the announcement of Pfizer (which left me very perplexed not because of the degree of success, which I cannot verify, but because of the storage difficulties, which is evident) the announcement of this new Moderna vaccine has arrived.
Modern vaccine: on paper it has many, many more advantages than Pfizer's
The vaccine developed from Moderna gives hope for many other things, not just the declared efficacy of 94,5%. It can be a much more distributed and distributable vaccine, because above all it is "cheap". On a logistical level, in fact, there is no need to cool the product to -80°. We don't need a whole new cold chain and refrigerators.
And it is not necessary, in the Moderna vaccine, a factor that immediately it had left me very perplexed. The need to transport it in suitcases (32 kilos each) full of dry ice to be continually replenished during the journey, to avoid its deterioration. Only the USA and Canada had the ability to produce all this dry ice in a reasonable time. Well, in the Moderna vaccine you don't need this mountain of dry ice for transport.
This on an economic level translates into tangible differences.
- Cost of a dose of Pfizer vaccine: 16 euros.
- Cost of a dose of AstraZeneca vaccine: 2 euros.
We will see the price of this Moderna vaccine, which I recorded at the time as “the fastest start of a vaccine study ever.” And in any case, before the scientific world reads all the documents produced very carefully, what I read are important declarations, with a strong economic impact (especially on the stock market) and nothing more.
